Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 1 Liver Neoplasms 1 Liver Diseases 1 Hepatitis C 1

Interventions

Sorafenib 4 Blood Specimen Collection 4 lenvatinib 3 sintilimab 2 halofantrine 2 camrelizumab 2 Liver Transplantation 2 Antibodies 2 trametinib 1 toripalimab 1 titanium silicide 1 tislelizumab 1 pembrolizumab 1 ledipasvir, sofosbuvir drug combination 1 genexol-PM 1 gadolinium ethoxybenzyl DTPA 1 fluorocholine 1 bavituximab 1 avatrombopag 1 aumolertinib 1 atezolizumab 1 User-Centered Design 1 Sunitinib 1 Sufentanil 1 Sofosbuvir 1 Shadowing Technique, Histology 1 Ropivacaine 1 Ribavirin 1 Radiotherapy 1 Radiosurgery 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Liver Diseases × Sofosbuvir × Clear all

NCT02717949 2019-01-08

Optimal

University of Texas Southwestern Medical Center

Phase 4 Terminated

Hepatitis C, Liver Diseases, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡